First Republic Investment Management Inc. boosted its holdings in Ascendis Pharma A/S (NASDAQ:ASND – Get Rating) by 17.3% in the third quarter, according to its most recent filing with the SEC. The institutional investor owned 15,000 shares of the biotechnology company's stock after buying an additional 2,215 shares during the period. First Republic Investment Management Inc.'s holdings in Ascendis Pharma A/S were worth $1,549,000 as of its most recent SEC filing.
A number of other institutional investors have also bought and sold shares of the business. Virtus ETF Advisers LLC increased its stake in Ascendis Pharma A/S by 4.9% in the 2nd quarter. Virtus ETF Advisers LLC now owns 2,856 shares of the biotechnology company's stock worth $265,000 after buying an additional 134 shares in the last quarter. Guggenheim Capital LLC increased its stake in Ascendis Pharma A/S by 7.2% in the 1st quarter. Guggenheim Capital LLC now owns 2,008 shares of the biotechnology company's stock worth $236,000 after buying an additional 135 shares in the last quarter. Envestnet Asset Management Inc. increased its stake in Ascendis Pharma A/S by 14.4% in the 1st quarter. Envestnet Asset Management Inc. now owns 2,246 shares of the biotechnology company's stock worth $264,000 after buying an additional 282 shares in the last quarter. US Bancorp DE grew its position in shares of Ascendis Pharma A/S by 29.2% during the third quarter. US Bancorp DE now owns 1,253 shares of the biotechnology company's stock valued at $130,000 after purchasing an additional 283 shares in the last quarter. Finally, Private Ocean LLC purchased a new position in shares of Ascendis Pharma A/S during the third quarter valued at about $49,000.
Get Ascendis Pharma A/S alerts:Analysts Set New Price Targets
A number of research analysts have recently weighed in on ASND shares. The Goldman Sachs Group started coverage on Ascendis Pharma A/S in a research report on Thursday, October 20th. They set a "buy" rating and a $174.00 price objective for the company. Morgan Stanley increased their price target on shares of Ascendis Pharma A/S from $146.00 to $148.00 and gave the company an "overweight" rating in a report on Tuesday, November 15th. Oppenheimer increased their price target on shares of Ascendis Pharma A/S from $144.00 to $150.00 in a report on Thursday, November 3rd. SVB Leerink lowered their price target on shares of Ascendis Pharma A/S from $168.00 to $148.00 and set an "outperform" rating for the company in a report on Monday, November 14th. Finally, StockNews.com began coverage on shares of Ascendis Pharma A/S in a report on Wednesday, October 12th. They issued a "sell" rating for the company. One analyst has rated the stock with a sell rating and eleven have assigned a buy rating to the company. According to MarketBeat.com, Ascendis Pharma A/S currently has an average rating of "Moderate Buy" and a consensus target price of $160.27.
Ascendis Pharma A/S Stock Performance
Shares of NASDAQ:ASND opened at $123.50 on Thursday. The firm has a market cap of $7.04 billion, a PE ratio of -13.41 and a beta of 0.54. The firm's 50 day simple moving average is $119.87 and its 200-day simple moving average is $108.85. The company has a debt-to-equity ratio of 1.18, a quick ratio of 6.83 and a current ratio of 7.56. Ascendis Pharma A/S has a one year low of $61.58 and a one year high of $134.52.Ascendis Pharma A/S (NASDAQ:ASND – Get Rating) last issued its quarterly earnings data on Wednesday, November 2nd. The biotechnology company reported ($3.05) earnings per share (EPS) for the quarter, missing the consensus estimate of ($2.52) by ($0.53). The business had revenue of $15.41 million for the quarter, compared to analysts' expectations of $10.67 million. Ascendis Pharma A/S had a negative net margin of 1,473.30% and a negative return on equity of 71.44%. As a group, equities analysts predict that Ascendis Pharma A/S will post -9.52 EPS for the current year.
About Ascendis Pharma A/S
(Get Rating)
Ascendis Pharma A/S is a biopharmaceutical company, which engages in the development of drug candidates. It specializes on its TransCon technologies to create prodrugs that provide for the predictable and sustained release of an unmodified parent drug. The company was founded by Jan Moller Mikkelsen, Dirk Vetter, and Harald Rau in September 2006 and is headquartered in Hellerup, Denmark.
Featured Stories
- Get a free copy of the StockNews.com research report on Ascendis Pharma A/S (ASND)
- Bed Bath & Beyond Is Circling the Drain
- Allegro Microsystems Is A Well-Positioned Semiconductor Stock
- Scotts Miracle-Gro Hits Bottom, Reversal In Play
- Altria is a Great Recession Stock, Long-Term Outlook Uncertain
- Novavax Shares Jumped in January While Others Slipped
Want to see what other hedge funds are holding ASND? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Ascendis Pharma A/S (NASDAQ:ASND – Get Rating).
Receive News & Ratings for Ascendis Pharma A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ascendis Pharma A/S and related companies with MarketBeat.com's FREE daily email newsletter.